ACWF iShares MSCI Global Multifactor ETF

0.00 (0.0%)
Last Updated: 20:00:00
Delayed by 15 minutes

Register Free for Streaming Quotes & Tools

Register for Free to get streaming quotes, interactive charts, trades, portfolio, live options flow and more.


Draw Mode:

Volume 0
Bid Price
Ask Price
News -
Day High


52 Week Range


Day Low
Company Name Etf Ticker Symbol Market Type
iShares MSCI Global Multifactor ETF ACWF AMEX Exchange Traded Fund
  Price Change Change Percent Etf Price Last Traded
0.00 0.0% 32.7935 20:00:00
Open Price Low Price High Price Close Price Prev Close
Trades Volume Avg Volume 52 Week Range
0 0 - 28.87 - 34.37
Last Trade Time Type Quantity Etf Price Currency
- 0  32.7935 USD

iShares MSCI Global Multifactor ETF Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
118.06M 3.60M - 3.42M -15.06M -4.18 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

News iShares MSCI Global Mult...

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No ACWF Message Board. Create One! See More Posts on ACWF Message Board See More Message Board Posts

ACWF Historical

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.
1 Month0.
3 Months0.
6 Months0.
1 Year29.3134.3728.8731.959,6193.4811.89%
3 Years29.5439.5828.8735.6114,8813.2511.01%
5 Years30.748539.5820.749930.4224,2292.056.65%

The investment seeks to track the investment results of the NYSE® FactSet® Global Genomics and Immuno Biopharma IndexTM. The fund generally will invest at least 80% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. -null-.